

## NEWSLETTER

### New interesting findings for the tumor marker **UBC® Rapid** Result from a new German multicenter study

Stockholm, 21.3.2016

At this year's EAU (European Association of Urology) meeting in Munich, March 11-15, a German multi-center study on **UBC® Rapid** was presented. Responsible for the study was Dr Thorsten Ecke, Helios Hospital, Department of Urology, Bad Sarrow. Urine samples were analyzed by **UBC® Rapid** POC test and evaluated quantitatively. The study showed very high sensitivity and specificity for high grade tumors generally 71/94%, and for CIS patients the sensitivity was even higher 87%. The authors concluded that **UBC® Rapid** should be added in the diagnostics for high risk bladder cancer and in particular for CIS patients with tumors in the bladder.

For further information, please contact:

Lars Skoglund  
Vice President Sales & Marketing  
IDL Biotech AB (publ)  
+46 8 799 67 50

IDL Biotech AB (publ) is a public Swedish Biotech company, specialized in the field of in vitro diagnostics within Oncology and Bacteriology. The company develops, manufacture and market high quality in vitro diagnostic products enabling reliable diagnosis for efficient patient management in conditions of high clinical concern. IDL's products are distributed mainly in Europe and Asia. IDL Biotech is listed on the Swedish equities market place, Aktietorget.

IDL Biotech AB (publ)

P.O. Box 11151  
SE-161 11 Bromma  
Sweden

Visiting address:  
Karlsbodavägen 39  
Bromma

Phone: +46 8 799 67 50  
Fax: +46 8 799 93 20  
idlbitech@idl.se  
Corp Id No: 556339-4203